Navigation Links
Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
Date:5/5/2009

SAN DIEGO, May 5, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced it will report first quarter 2009 financial results after the NASDAQ Global Market closes on Monday, May 11, 2009. That same afternoon, Jack Lief, Arena's President and Chief Executive Officer, and Robert E. Hoffman, Arena's Vice President, Finance and Chief Financial Officer, will host a conference call at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to discuss the financial results for the first quarter 2009 and to provide a business and financial update.

The conference call may be accessed by dialing 877.857.6151 for domestic callers and 719.325.4806 for international callers. Please specify to the operator that you would like to join the "Arena Pharmaceuticals First Quarter 2009 Earnings Call." The conference call will be webcast live under the investor relations section of Arena's website at www.arenapharm.com, and will be archived there for 30 days following the call. Please connect to Arena's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for weight management. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck & Co., Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc.

Arena Pharmaceuticals(R) and Arena(R) are registered service marks of the company. "APD" is an abbreviation for Arena Pharmaceuticals Development.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. Such forward-looking statements include statements about Arena's strategy, internal and partnered programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, Arena's ability to obtain additional funds, the timing, success and cost of Arena's lorcaserin program and other of its research and development programs, the risk that results of clinical trials or preclinical studies may not be predictive of future results, clinical trials and studies may not proceed at the time or in the manner Arena expects or at all, Arena's ability to partner lorcaserin or other of its compounds or programs, the timing and ability of Arena to receive regulatory approval for its drug candidates, Arena's ability to obtain and defend its patents, and the timing and receipt of payments and fees, if any, from Arena's collaborators. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

    Contacts:  Jack Lief
    President and Chief Executive Officer

    Cindy McGee
    Senior Communications Associate

    Arena Pharmaceuticals, Inc.
    858.453.7200, ext. 1479

    Mary Claire Duch
    WeissComm Partners
    Media Relations
    212.301.7228


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
2. Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
3. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
4. Arena Pharmaceuticals to Report Third Quarter 2008 Financial Results and to Host Conference Call and Webcast on Thursday, October 30, 2008
5. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
6. Arena Pharmaceuticals to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
9. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
10. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
11. ThreeWire Expands Presence in the Pharmaceutical Arena
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... London, June 28, 2017 (PRWEB) , ... ... ... The latest release of Siemens’ STAR-CCM+® software for multiphysics computational fluid dynamics ... automated product design exploration and optimization. STAR-CCM+ version 12.04 introduces Design Manager, ...
(Date:6/28/2017)... ... 28, 2017 , ... Studies indicate that replacing damaged brain cells with those ... disease. But what has not been determined is the optimal stage during differentiation of ... , A new study coming out of Singapore, recently published in STEM CELLS Translational ...
(Date:6/27/2017)... AZ (PRWEB) , ... June 27, 2017 , ... ... world’s first brain mirroring wellness product via Kickstarter campaign on June 15th to ... have already pre-ordered the B2v2, exceeding the original Kickstarter goal by more than ...
(Date:6/27/2017)... ... 27, 2017 , ... According to a recent report from ... not have negative short- or long-term effects on benthic communities. , The ... located at the Puget Sound Naval Shipyard & Intermediate Maintenance Facility in Bremerton, ...
Breaking Biology Technology:
(Date:5/23/2017)... GENOA, Italy , May 23, 2017  Hunova, the first robotic ... and trunk, has been officially launched in Genoa, Italy ... Europe and the USA . The ... launched on the market by the IIT spin-off Movendo Technology thanks to ... view the Multimedia News Release, please click: ...
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
(Date:4/13/2017)... April 13, 2017 UBM,s Advanced Design and ... will feature emerging and evolving technology through its 3D ... will run alongside the expo portion of the event ... and demonstrations focused on trending topics within 3D printing ... and manufacturing event will take place June 13-15, 2017 at ...
Breaking Biology News(10 mins):